Benzinga | Aug 26, 2021 04:03PM EDT

Avita Therapeutics Q4 EPS $(0.19) Beats $(0.29) Estimate, Sales $10.30M Beat $7.88M Estimate

Avita Therapeutics (NASDAQ:RCEL) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.29) by 34.48 percent. The company reported quarterly sales of $10.30 million which beat the analyst consensus estimate of $7.88 million by 30.71 percent.